Podium to Practice: Chicago 2026 – LUNG: TRITON study

Podium to Practice: Chicago 2026 – LUNG: TRITON study

Podium to Practice: Chicago 2026

Studies / Trials Discussed

8515 – Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.

Icon Chair Speaker

Chair

Dr. Barb Melosky

Icon Chair Speaker

Speakers

Dr. Paul Wheatley-Price

Dr. Rosalyn Juergens

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

8515 – Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON study.
Tagged